- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI
- Combination Product · Drug · Other
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 1,001 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 73
- States / cities
- Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more
- Conditions
- Asthma
- Interventions
- BDA MDI, AS MDI
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more
- Conditions
- Asthma
- Interventions
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Boerne, Texas
- Conditions
- Exercise Induced Bronchospasm
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler
- Combination Product
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 6
- States / cities
- Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Psoriasis
- Interventions
- M1095 (Sonelokimab), Placebo, Secukinumab
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more